1 Cell Biology Research Group, Biotechnology Research Center , Twisha, Tripoli, Libya .
Cancer Biother Radiopharm. 2014 Mar;29(2):87-90. doi: 10.1089/cbr.2013.1557. Epub 2013 Nov 20.
Rituximab is an effective immunotherapy for CD20-positive B-cell non-Hodgkin's lymphoma. However, some patients show resistance, particularly those suffering from more aggressive lymphoma types, such as Burkitt's lymphoma. Hence, Rituximab is commonly combined with several chemotherapeutic drugs. With a view to reduce the number of such drugs, we examined the effect of combining Rituximab individually with hydroxyurea, vincristine, or etoposide on the killing of Ramos Burkitt lymphoma cell line type I. Cell death was examined by using Annexin-V/propidium iodide staining. Combining Rituximab with hydroxyurea or vincristine resulted in a synergistic effect, whereas combining it with etoposide resulted in a subadditive effect. In single treatments, the percentage of cell death ranged from 23% (Rituximab) to 36% (hydroxyurea). Combining Rituximab with hydroxyurea or vincristine resulted in a synergistic effect (83% and 74% killing, respectively). In contrast, only a subadditive effect was noticed with etoposide (36%). We conclude that the synergistic effect of Rituximab with hydroxyurea or vincristine is worthy of further study, and that further in vitro screening of chemotherapeutics might identify chemo-immunotherapeutic combinations that are effective in vivo but less toxic than currently used regimens.
利妥昔单抗是一种有效的针对 CD20 阳性 B 细胞非霍奇金淋巴瘤的免疫疗法。然而，一些患者表现出耐药性，特别是那些患有更具侵袭性的淋巴瘤类型的患者，如伯基特淋巴瘤。因此，利妥昔单抗通常与几种化疗药物联合使用。为了减少此类药物的数量，我们研究了利妥昔单抗分别与羟基脲、长春新碱或依托泊苷联合使用对杀死 Ramos 伯基特淋巴瘤细胞系 I 型的影响。通过使用 Annexin-V/碘化丙啶染色来检测细胞死亡。利妥昔单抗与羟基脲或长春新碱联合使用产生协同作用，而与依托泊苷联合使用则产生相加作用。在单一治疗中，细胞死亡的百分比范围从 23%（利妥昔单抗）到 36%（羟基脲）。利妥昔单抗与羟基脲或长春新碱联合使用产生协同作用（分别为 83%和 74%的杀伤）。相比之下，依托泊苷仅观察到相加作用（36%）。我们得出结论，利妥昔单抗与羟基脲或长春新碱的协同作用值得进一步研究，并且进一步的体外化疗筛选可能会确定在体内有效的化疗免疫治疗组合，其毒性比目前使用的方案更小。
